FDA Approves DARZALEX FASPRO® for Newly Diagnosed Multiple Myeloma Patients
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) recently approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and …
FDA Approves DARZALEX FASPRO® for Newly Diagnosed Multiple Myeloma Patients Read More